

COMPANY OVERVIEW

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, including major depressive disorder, neuropathic pain social anxiety disorder and suicidal ideation. AV-101 is an oral NMDAR GlyB (N-methyl-D-aspartate receptor glycine B) antagonist, belonging to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat Major Depressive Disorder faster than currently available FDA-approved antidepressants which, if effective, take many weeks to months to achieve therapeutic benefits. With the at-home convenience of an oral therapy, AV-101 has the potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants.

PH94B was developed from proprietary compounds called pherines. With nasal spray administration, PH94B acts locally on peripheral nasal chemosensory receptors that trigger rapid activation of the hypothalamic-limbic areas of the brain associated with social anxiety disorder. This mechanism of pharmacological action, the rapid onset of efficacy, and the excellent safety and tolerability profile shown in clinical trials make PH94B an excellent product candidate for the acute treatment of patients with social anxiety disorder, which affects as many as 15 million adults in the U.S.

RECENT NEWS

VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101

Nov 29 2018, 8:30 AM EST

STOCK OVERVIEW

| | |
|---------------|-------------------|
| Symbol | VTGN |
| Exchange | Nasdaq |
| Market Cap | 45.69m |
| Last Price | \$1.77 |
| 52-Week Range | \$0.8101 - \$2.44 |

12/10/2018 04:00 PM EST

INVESTOR RELATIONS

VistaGen Therapeutics, Inc.
Mark A. McPartland
Vice President, Corporate
Development
(650) 577-3606
markmcp@vistagen.com

KCSA Strategic Communications
Valter Pinto / Allison Soss
(212) 896-1254 / (212) 896-1267
VistaGen@KCSA.com

MANAGEMENT TEAM

Shawn K. Singh

Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.

Founder, President, Chief Scientific Officer and Director

Mark A. Smith, M.D., Ph.D.

Chief Medical Officer

Jerrold D. Dotson, CPA

Vice President, Chief Financial Officer and Secretary

Mark A. McPartland

Vice President of Corporate Development

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.